Ardelyx (ARDX) Shares Outstanding (Weighted Average) (2013 - 2026)
Ardelyx (ARDX) reported Shares Outstanding (Weighted Average) of $245.9 million for Q1 2026, up 3.03% on a YoY basis from $238.6 million in Q1 2025, and up 2.0% quarter-over-quarter from $241.0 million in Q4 2025.
Ardelyx (ARDX) Shares Outstanding (Weighted Average) (2013 - 2026) Analysis & Trends
Ardelyx has reported Shares Outstanding (Weighted Average) for 14 years, with the latest figure at $245.9 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.03% year-over-year to $245.9 million; the trailing twelve-month figure through Mar 2026 stood at $245.9 million (up 3.03% YoY), and the FY2025 full-year result was $241.0 million, up 2.47% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $245.9 million, up from $241.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $245.9 million in Q1 2026, with the low at $130.9 million in Q1 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $210.2 million across 5 years, with a median of $227.9 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) soared 64.32% — and 2025, when it advanced 2.38%.
- Ardelyx's Shares Outstanding (Weighted Average) stood at $158.7 million in 2022, then jumped by 38.21% to $219.3 million in 2023, then advanced by 7.25% to $235.2 million in 2024, then increased by 2.47% to $241.0 million in 2025, then gained by 2.0% to $245.9 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $245.9 million (Q1 2026), $241.0 million (Q4 2025), and $239.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 245.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 245.86 Mn |
| Dec 31, 2025 | 241.03 Mn |
| Jun 30, 2025 | 239.93 Mn |
| Mar 31, 2025 | 238.62 Mn |
| Dec 31, 2024 | 235.23 Mn |
| Sep 30, 2024 | 234.52 Mn |
| Jun 30, 2024 | 233.82 Mn |
| Mar 31, 2024 | 233.07 Mn |
| Dec 31, 2023 | 219.33 Mn |
| Sep 30, 2023 | 222.78 Mn |
| Jun 30, 2023 | 211.01 Mn |
| Mar 31, 2023 | 207.02 Mn |
| Dec 31, 2022 | 158.69 Mn |
| Sep 30, 2022 | 165.10 Mn |
| Jun 30, 2022 | 145.54 Mn |
| Mar 31, 2022 | 130.94 Mn |
| Dec 31, 2021 | 104.21 Mn |
| Sep 30, 2021 | 100.48 Mn |
| Jun 30, 2021 | 100.04 Mn |
| Mar 31, 2021 | 97.18 Mn |